Aurinia Pharmaceuticals Archives

Tag: Aurinia Pharmaceuticals

Data Shows Voclosporin Preserves Kidney Function for Three Years

July 19,2023 The LRA is pleased to share news announced by Aurinia Pharmaceuticals of published results showing that the lupus treatment, voclosporin (Lupkynis) preserved kidney function up to three years among lupus nephritis. These results of the Phase 3, double-blind, placebo-controlled AURORA 2 extension study were published in the official peer-reviewed professional journal of the […] Read More

The Lupus Research Alliance Teams Up with the New York Jets for New Jersey Walk with Us to Cure Lupus 20th Anniversary Event

EAST RUTHERFORD, NEW JERSEY. May 6, 2023. An enthusiastic crowd of nearly 1,500 supporters came together today at MetLife Stadium for the Lupus Research Alliance (LRA) 2023 New Jersey Walk with Us to Cure Lupus to raise nearly $500,000 for lupus research as well as public awareness of the serious and commonly misdiagnosed autoimmune disease. […] Read More

Lupkynis® (voclosporin) Granted Marketing Authorization in the European Union for Lupus Nephritis

September 21, 2022 Lupkynis® (voclosporin) was just granted marketing authorization in the European Union as a new treatment for adults with lupus nephritis, the kidney damage associated with lupus. The drug had also been approved this past January in the U.S. to treat adults with lupus nephritis in combination with a background immunosuppressive medication in […] Read More

2022 New Jersey Walk with Us to Cure Lupus Raises Awareness and Funds for Commonly Misdiagnosed Autoimmune Disease

May 14, 2022 EAST RUTHERFORD, NEW JERSEY. May 14, 2022. The Lupus Research Alliance (LRA) brought together thousands of people to MetLife Stadium for the 2022 New Jersey Walk with Us to Cure Lupus to raise lupus awareness. The MetLife walk marked the 20th anniversary of the LRA’s national Walk Program. As Honorary Chair of […] Read More

Aurinia Announces Positive Long-Term Results on Lupykinis™ for Lupus Nephritis

December 9, 2021 The LRA is pleased to share positive topline three-year efficacy and safety results reported today by Aurinia Pharmaceuticals from the AURORA 2 continuation study of Lupkynis™ (voclosporin). These results provide the longest available data for an FDA-approved medicine in lupus nephritis. The U.S. Food and Drug Administration approved Lupkynis arlier this year […] Read More

Lupus Research Alliance Breaking Through Gala Sets New Record, Raising $7.5 Million for Lupus Research

New York, NY. November 23, 2021 – Last night’s Lupus Research Alliance (LRA) Breaking Through Gala was the most successful in the history of the organization raising $7.5 million – double that of any previous year — for lupus research. The hundreds attending the hybrid festivities in-person at the Ziegfeld Ballroom and online were inspired by […] Read More

The Lupus Research Alliance Unites Global Community at Immersive Virtual Walk Experience to Support Lupus Research

NEW YORK, NY. September 30, 2021. The Lupus Research Alliance (LRA) is pleased to invite the global community to join together as one at its virtual ManyOne Can. Walk with Us to Cure Lupus celebratory event. The aim is to unite and inspire the entire world on one day, Saturday, October 2, 2021, to achieve one […] Read More

LRA Congratulates Aurinia on Published Results with FDA-Approved Lupkynis™

May 10, 2021 The highly prestigious medical journal The Lancet published the results of Aurinia’s Phase 3 AURORA 1 study testing Lupkynis™ (voclosporin) in adults with lupus nephritis. Lupkynis was approved by the U.S. Food and Drug Administration based on these data. The AURORA 1 study results showed that Lupkynis in combination with the commonly used […] Read More

Lupus Research Alliance Hails Approval of Aurinia’s Lupkynis(TM) (voclosoporin)

First Oral Treatment for Lupus Nephritis; Second Lupus Treatment to Receive FDA Approval in Past Month NEW YORK, NY. January 22, 2021. The Lupus Research Alliance (LRA) is excited to share that the U.S. Food and Drug Administration (FDA) approved the use of Aurinia Pharmaceuticals’ LupkynisTM (voclosporin) as the first oral treatment developed specifically for […] Read More

Results of Two Voclosporin Trials Presented at Key Medical Meeting

October 22, 2020 Aurinia Pharmaceuticals announced that data taken from a combined analysis of two trials, AURA-LV and AURORA underscored the potential for voclosporin to offer a tool to treat lupus nephritis. Results from 534 patients from both trials was presented at the American Society of Nephrology Kidney Week 2020 meeting by Dr. Brad Rovin, […] Read More

LRA Statement: Potential Lupus Nephritis Drug Voclosporin Granted Priority Review by the U.S. FDA

NEW YORK, NY. July 22, 2020. The Lupus Research Alliance congratulates Aurinia Pharmaceuticals Inc. on acceptance of its NDA filing and priority review designation by the U.S. Food and Drug Administration for its investigational drug voclosporin for lupus nephritis. A serious inflammation of the kidneys, lupus nephritis is one of the most common complications of […] Read More

Aurinia Completes NDA and Requests Priority Review of Voclosoporin by FDA for Lupus Nephritis

May 28, 2020 The Lupus Research Alliance is pleased to share that Aurinia Pharmaceuticals Inc submitted a New Drug Application (NDA) to the U.S. FDA for voclosporin as a potential treatment for lupus nephritis with request for a priority review. Lupus nephritis is one of the most common complications of systemic lupus erythematosus, a serious […] Read More